A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity

Haematologica. 2004 Dec;89(12):1534-6.

Abstract

Sixteen patients with stage III multiple myeloma (MM) and a median age of 51 years were treated with autografting followed by reduced intensity conditioning allotransplantation (RICT). Nine patients are alive in remission at a median of 30 months after their transplants, one patient is alive in relapse and 6 patients died of progressive disease (5) or extensive chronic graft-versus-host disease, infections and progressive disease (1). We suggest that this two-step approach is feasible and it has strong anti-myeloma activity.

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Combined Modality Therapy
  • Cyclophosphamide / pharmacology
  • Disease Progression
  • Disease-Free Survival
  • Feasibility Studies
  • Female
  • Graft vs Host Disease / etiology
  • Graft vs Host Disease / mortality
  • Graft vs Host Disease / prevention & control
  • Granulocyte Colony-Stimulating Factor / pharmacology
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Infections / etiology
  • Infections / mortality
  • Male
  • Melphalan / therapeutic use
  • Middle Aged
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / therapy*
  • Peripheral Blood Stem Cell Transplantation / methods*
  • Postoperative Complications / mortality
  • Remission Induction
  • Salvage Therapy
  • Survival Analysis
  • Transplantation Conditioning / methods*
  • Transplantation, Autologous / methods*
  • Transplantation, Homologous / methods*
  • Treatment Outcome
  • Vidarabine / analogs & derivatives
  • Vidarabine / therapeutic use
  • Whole-Body Irradiation

Substances

  • Immunosuppressive Agents
  • Granulocyte Colony-Stimulating Factor
  • Cyclophosphamide
  • Vidarabine
  • fludarabine
  • Melphalan